STOCK TITAN

Arrowhead Research Corporation - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.

Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.

The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.

With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences earnings
-
Rhea-AI Summary
Arrowhead Pharmaceuticals has filed an application to initiate a Phase 1/2 clinical trial of ARO-DUX4, its investigational RNA interference therapeutic for facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 is the first clinical candidate utilizing Arrowhead's proprietary TRiMTM platform to target disease-associated genes in skeletal muscle.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
conferences
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. hosted an R&D Day to discuss progress towards its goal of having 20 clinical stage or marketed products by 2025. The company highlighted advancements in its TRiM platform, including improved knockdown of target genes and expanded delivery to different cell types. Presentations were given on various programs, including CNS, pulmonary, liver-targeted, and cardiometabolic programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.64%
Tags
conferences

FAQ

What is the current stock price of Arrowhead Research Corporation (ARWR)?

The current stock price of Arrowhead Research Corporation (ARWR) is $19.75 as of December 23, 2024.

What is the market cap of Arrowhead Research Corporation (ARWR)?

The market cap of Arrowhead Research Corporation (ARWR) is approximately 2.4B.

What is the primary focus of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals focuses on developing gene-silencing therapies to treat intractable diseases by targeting the genes that cause them.

What is RNA interference (RNAi)?

RNA interference (RNAi) is a natural mechanism in living cells that inhibits the expression of specific genes, thereby affecting the production of certain proteins.

What is the TRiMTM platform?

The TRiMTM platform is Arrowhead's targeted RNAi molecule technology that uses ligand-mediated delivery for tissue-specific targeting, designed to simplify manufacturing and improve therapeutic precision.

Which diseases does Arrowhead Pharmaceuticals address?

Arrowhead's treatments target diseases such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Where is Arrowhead Pharmaceuticals headquartered?

Arrowhead Pharmaceuticals is headquartered in Pasadena, California.

What are the latest developments at Arrowhead Pharmaceuticals?

For the latest news and developments, visit Arrowhead Pharmaceuticals' official website or check recent press releases and updates.

How does Arrowhead's technology benefit patients?

Arrowhead's RNAi-based therapies aim to reduce the production of proteins that cause diseases, offering potential life-changing treatments for patients.

What are some advantages of the TRiMTM platform?

The TRiMTM platform's advantages include simplified manufacturing processes and enhanced tissue-specific targeting.

Is Arrowhead publicly traded?

Yes, Arrowhead Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol ARWR.

How can I invest in Arrowhead Pharmaceuticals?

You can invest in Arrowhead Pharmaceuticals by purchasing shares through a stockbroker or an online trading platform. The company's ticker symbol is ARWR.

Arrowhead Research Corporation

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

2.44B
118.89M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA